Loading clinical trials...
Loading clinical trials...
Phase 1b Double-Blind, Placebo-Controlled, Ascending Dose Trial: ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Conditions
Interventions
ORIN1001
Placebo
Locations
11
United States
St. Francis Sleep, Allergy & Lung Institute
Clearwater, Florida, United States
Mayo Clinic Hospital
Jacksonville, Florida, United States
Avanza Medical Research
Pensacola, Florida, United States
Coastal Pulmonary and Critical Care
St. Petersburg, Florida, United States
Loyola University Medical Center
Maywood, Illinois, United States
University of Iowa Hospital
Iowa City, Iowa, United States
Start Date
February 9, 2021
Primary Completion Date
December 30, 2025
Completion Date
December 30, 2025
Last Updated
May 30, 2025
NCT06238622
NCT07299695
NCT07466420
NCT06241560
NCT07407543
NCT05989698
Lead Sponsor
Orinove, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions